It's me again, still reporting from the American Society of Clinical Oncology (ASCO) annual meeting. We just got our first look at the clinical activity of Incyte's (INCY) - Get Incyte Corporation (INCY) Report immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with Bristol-Myers Squibb's (BMY) - Get Bristol-Myers Squibb Company Report Yervoy in melanoma patients. The Wall Street scrum around the Incyte poster was insane. 

Oh yeah, you're probably interesting in hearing about the data. Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response rate of 50%. A third patient reported stable disease so the disease control rate was 75%. The

Incyte press release and poster can be found here

Seeing a complete response is always a good sign, so while the number of patients treated in the 50 mg cohort is small, there's enough clinical activity here to justify running new combination studies of '360 and the PD-1 inhibitors from Bristol, Merck (MRK) - Get Merck & Co., Inc. (MRK) Report and others. 

We last saw data on '360 at the 25 mg dose when the ASCO abstracts were released in mid May.

TheStreet Recommends

Incyte shares rebounded big time when the '360 data were announced this afternoon.

INCY Price data by YCharts

Image placeholder title

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.